MARKET ACCESS 101

CAHR's industry-renowned Market Access 101 Conference will be held in-person on June 11th. This course is designed to educate market access professionals and other industry professions on the fundamentals of Canadian pharmaceutical access and reimbursement. Participants gain insights into Canadian reimbursement systems and Payers’ perspectives to develop a broader understanding of the multiple factors required to successfully navigate a product through market access and reimbursement processes.

CAHR is pleased to present the return of this industry classic – a primer on everything you need to know about Market Access in Canada, taught by experts in each subject, and the foundation of the Certified Market Access Professional credential. Our accomplished faculty will dive deeply into all aspects of our complex environment – from clinical evidence, HTA agencies and HTA submissions to private and public payers, PMPRB, patient engagement and patient support programs - to empower and reward delegates with information, insights and interpretations that will enhance their careers in Market Access.

AGENDA

9am
Breakfast

9:30am
Welcome & Housekeeping 
Emcees Sophie Rochon, Otsuka Canada Pharmaceutical Inc. and Peter Melnyk, Enoumena Consulting Inc.

9:45 am
Overview of Market Access and Canadian Landscape

Market Access in Canada is a broad field encompassing many different areas. Join Arvind Mani as he introduces the field, including what market access entails in the Canadian market and provides an overview of what market access professionals need to know, including an overview of the changing public policy landscape affecting the profession.
Arvind Mani, Morse Consulting

10:45am
Evidence – Clinical & Real World

This session will focus on the data expectations of payers and HTA bodies, as they evaluate/consider the value of new drug products for drug plan listing. In addition, we will review the evolving role of real-world evidence (RWE) in reimbursement.
Lindy Forte, Eversana

11:45am  
Networking Lunch

12:30pm
PMPRB

New PMPRB Regulations will be implemented July 1st. The price tests and guidelines that will be used to operationalize the Regulations are in flux. This presentation will discuss what we know and what we need to watch for in terms of the review of new patented drugs.
Anna Apostolakis, IQVIA

1:15pm
Introduction to the Private Payer Market

Join Shanta as she walks through a brief overview of private drug coverage in Canada: from where drugs fit overall into employer sponsored benefits, to a discussion on the different types of management strategies insurers use to control drug costs.
Shanta Zurock, Innomar Strategies

2:00pm
PSP Overview with a Focus on Impacts to Financial Assistance During COVID-19 Structuring a PSP to Support Market Access

This session will cover the basics of a Patient Support Program, including why PSP’s are needed in Canada, key elements of a PSP, a typical PSP journey, drug lifecycle considerations, high level vendor landscape, preparing for an RFP and metrics to measure success.

2:30pm
Networking Break

2:45pm
HTA Basics

This session will serve as an introduction to Health Technology Assessment (HTA) in Canada, encompassing the HTA review and drug reimbursement process. Additionally, the clinical and economic components of a HTA review will be explored such as the clinical summary, clinical evidence template, systematic literature reviews, indirect treatment comparisons, economic evaluations, decision modelling, sensitivity analyses, and budget impact analyses.
Catherine Beauchemin, Peripharm

4:00pm pCPA
This session will provide an overview of the pan-Canadian Pharmaceutical Alliance (pCPA) including its history, processes, outcomes, and outlook for the future.
Katherine Scott, Morse Consulting

5pm
Closing Remarks 
Emcees Sophie Rochon, Otsuka Canada Pharmaceutical Inc. and Peter Melnyk, Enoumena Consulting Inc.

Please note: if you're working towards your CMAP Certification
you MUST attend both Market Access 201 and Market Access 101.

Upon completion. you will be able to:

• Explain why market access is critical to commercial success
• Describe the market access players in the public and private payer environments
• Discuss how review processes, pricing and regulations impact public and private payer environments
• Find the information necessary to understand public and private submission processes
• Identify key players in the market access and reimbursement environments
• Discuss the intricacies of bringing a new drug to market in Canada
• Identify the key approvals pathways, processes and agencies involved in bringing a new drug to market in Canada
• Leverage a solid foundation in all areas of Patient Support Programs in Canada

Remember to check our website, which we suggest you bookmark, as that is where you will find updated information and announcements about all upcoming virtual and in-person programs.

* Registration code required for both patient groups and students. 
Please contact the CAHR office info@cahr-acrss.ca to obtain the code.

CAHR reserves the right to cancel or change speakers, content and date without prior notice. We assume no liability for these changes.

Cancellation Policy: For cancellations two (2) weeks or more in advance, delegates will receive a 75% refund. For cancellations made less than two (2) weeks in advance, no refunds are given. Delegate substitutions will be accepted at no cost.